Researchers develop promising way to find new cancer drugs
The enzymes in human cells known as histone deacetylases, or HDACs, are targets for a handful of anticancer drugs because of their ability to affect gene expression. Now, researchers from the University of Copenhagen have developed a new method to investigate how these enzymes work on a molecular level. This new method can also help identify more precise possible anti-cancer drug candidates at a very high pace.
All the cells in the human body share the same genes. But how our genes are expressed determines whether a cell becomes a brain cell or a liver cell. In addition, changes in gene expression often play a significant role in development of diseases.
One mechanism that contributes to the changes in gene expression is the interaction between the proteins called histones and enzymes known as HDACs. These enzymes help the cell divide and develop, which is the reason why they serve as targets for anti-cancer medicine: When you inhibit the enzymes, the cancer cells will stop dividing and growing further.
Despite being targets for clinically approved medicines, researchers do not know all the details of how they work in the cell. Now, researchers from the University of Copenhagen have developed a method that will help change that.
“We have shown details of how these enzymes interact with proteins around our DNA, and our method provides a new means for identifying possible anti-cancer drugs very quickly. In the study, we show that the method works: We synthesized a peptide that affected just the right parts of living human cells, using the same target as anti-cancer medicine uses today,” says Carlos Moreno-Yruela, postdoc at the Department of Drug Design and Pharmacology.
Unmodified peptide had effect
HDACs are a group of eleven different enzymes, which means that targeting them all at once with a non-selective medicine will result in affecting many essential processes in the body. This may also explain some of the side effects in the clinically approved HDAC-inhibiting anti-cancer medicine.
“Our detailed insight into the enzymes’ interactions gained with the new method provide hope for the development of more specific HDAC inhibitors with potential as drug candidates. This could bode well for the development of more sophisticated compounds for cancer therapy with fewer side effects,” says Professor Christian Adam Olsen.
Postdoc Carlos Moreno Yruela adding HDAC solution to microarray slides (photo: Joana Daradoumis)
In the study, the researchers used the new method for identifying peptides, which they resynthesized in larger amounts and subjected to human cells. The results were exactly what they hoped: The expected HDACs were also inhibited in living cells.
“We were surprised to see such a prominent effect of an unoptimized peptide in cells. Normally, one would need to introduce a variety of modifications to optimize its properties. But this, almost fully natural, peptide had a really potent effect, which emphasizes the potential of our findings,” says Christian Adam Olsen.
The researchers now hope to use the method for identifying promising drug candidates which could go on to pre-clinical testing.
Read the entire study: “Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases”
The study was funded by the University of Copenhagen, Carlsberg Foundation, the Lundbeck Foundation and the European Research Council.
Contact
Professor Christian Adam Olsen
+45 22 28 20 06
cao@sund.ku.dk
Press Officer Mathias Traczyk
93 56 58 35
mathias.traczyk@sund.ku.dk